Together, these data demonstrate that our ex vivo-generated cDC1s superiorly cross-present tumor antigens and thereby competently boost the expansion of patient-derived tumor-reactive HA-1 specific CD8+ T cells ex vivo. The gene discussed is CD8A; the disease is neoplasm.